MARCIO NATTAN PORTES SOUZA
Índice h a partir de 2011
4
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
8 resultados
Resultados de Busca
Agora exibindo 1 - 8 de 8
conferenceObject Recurrent visits to the Emergency Department (ED) due to Headache: economic burden and epidemiological profile(2019) SOUZA, Marcio Nattan P.; CALDERARO, Marcelo; OLIVEIRA, Ana Paula D. S.; KUBOTA, Gabriel T.; ZAMBON, Lucas S.; ANGHINAH, Renato; JORDAO, Mauricio R.conferenceObject Migraine Burden and Impact: Survey Results From 6 Countries in South America, Asia, and Australia(2021) SOUZA, M. Nattan Portes; COHEN, J. M.; LENGIL, T.; DUSSELIER, M.; GEENS, M.conferenceObject International availability of headache medications - an ongoing global survey of the International Headache Society(2023) PULEDDA, Francesca; BOER, Irene de; GARCIA-AZORIN, David; MESSINA, Roberta; AL-KARAGHOLI, Mohammad Al-Mahdi; SOUZA, Marcio Nattan Portes; DHAEM, Olivia Begasse de; GOICOCHEA, Maria-Teresa; TASSORELLI, Cristina; MAY, ArneconferenceObject Profile of migraine investigation in the emergency department of a tertiary hospital in Brazil: the exceeding use of Brain CT(2021) SOUZA, M. N.; KUBOTA, G.; FONSECA, A. P.; CALDERARO, M.; KUSTER, G.; AO, M. Jord; CARVALHO, R.; OLIVEIRA, A. P.; PINCERATO, R.conferenceObject A SURVEY ASSESSING THE BURDEN AND IMPACT OF MIGRAINE ACROSS 6 COUNTRIES IN SOUTH AMERICA, ASIA, AND AUSTRALIA(2020) SOUZA, Marcio Nattan Portes; COHEN, Joshua M.; LENGIL, Tamar; DUSSELIER, Matthias; GEENS, Magali- Bridging the gaps of headache care for underserved populations: Current status of the headache field in Latin America(2022) LISICKI, Marco; SOUZA, Marcio Nattan Portes; OLIVEIRA, Arao Belitardo de; RUBIO-BELTRAN, Eloisa; LABASTIDA-RAMIREZ, Alejandro; ASHINA, Messoud; PERES, MarioObjective To evaluate the current status of specialized headache care and research in Latin America. Background Latin America corresponds to about 9% of the global population. There is considerably limited access to headache services, and very few resources are allocated to headache research in this region. Methods The study consisted of two parts. First, in order to evaluate headache-related scientific output from Latin American countries we performed a 10-year bibliometric analysis and contrasted the results with a human developmental index-adjusted projection model. Secondly, we conducted a survey addressing different aspects of headache research, education, clinical practice, and awareness among members of the Latin American Headache Society. Results During the last 10 years 70% of Latin American countries published less than three articles regarding headache disorders. This contrasts with an average expected publication rate of 889 scientific papers. Indeed, none of the countries fulfilled their human developmental index - adjusted projected scientific output, with Brazil being the closest reaching 84.1% of what would be considered optimal according to the model. From the 86 headache-dedicated professionals that responded to the survey, most (64%) reported not having a headache specialization programme of any kind available in their countries. The biggest impediments towards conducting research observed by participants were the lack of time (39%), resources (22%), and training (21%). Conclusions Latin American countries have a considerable gap in headache-related scientific production, and also in formal education, research, and implementation of multidisciplinary services. Access to specialized headache care is particularly limited for patients with lower economic income.
- Place of next generation acute migraine specific treatments among triptans, non-responders and contraindications to triptans and possible combination therapies(2023) BOER, Irene de; VERHAGEN, Iris Elsa; SOUZA, Marcio Nattan Portes; ASHINA, MessoudBackground: For many years triptans have been the cornerstone of acute migraine treatment. Nevertheless, treatment with triptans may not always be initiated due to contraindications (seen in approximately one fifth of patients) or inadequate response (seen in approximately one third of patients). New acute therapies, including 5-hydroxytryptamine (5-HT)(1F) receptor agonists, also known as ditans (lasmiditan) and small molecule antagonists of the calcitonin gene-related peptide receptor, also known as gepants (rimegepant and ubrogepant), may be an effective alternative. Methods: We searched Pubmed for keywords, summarized the literature and provided a comprehensive review on the place of next generation acute migraine specific treatments among triptans. Results and conclusion: Post-hoc analyses reported no differences in efficacy of gepants/ditans between responders and non-responders to triptans, but research is hampered by lack of consensus on the definition of non-responder. Due to (partially) overlapping mechanisms of action, it remains unknown whether combination therapy with lasmiditan, gepants and triptans will have added value over monotherapy. Preclinical studies and post-hoc analyses cautiously indicate that these new drugs are safe for patients with cardiovascular risk factors. However, long-term studies are needed to prove cardiovascular safety. The risk of developing medication overuse headache may differ between triptans, ditans and gepants, but further studies are needed to confirm this difference. Head-to-head randomized controlled trials of acute therapies and combinations of therapies are needed to determine their place in migraine treatment among established therapies.
conferenceObject Online survey revealing patients' journey throughout the Brazilian healthcare system(2021) SOUZA, M. N.; KUBOTA, G.; SIMIONI, C.; CALDERARO, M.; MATTOS, B.; CHAVES, L.; COSTA, B.; SANTOS, F. R.; PASSARELLI, V.; FORTINI, I.